Biologics Leaders: Mo Pinto

Could you share a bit about your journey into science, particularly what ignited your passion?

My interest in science began in childhood, where simple experiences like planting trees sparked a lasting fascination with nature and experimentation. This curiosity continued to grow throughout my teenage years, as I began exploring chemistry through hands-on projects such as etching circuits and mixing compounds. By secondary school, chemistry had firmly become my favourite subject, motivating me to study well beyond the classroom curriculum. This early passion naturally led me to pursue a BSc in Chemistry, followed by a PhD in Polymer Science. After eight years in academia, I moved into the industry for advanced chemical development over the last two decades, and a particularly valuable opportunity at a CDMO significantly strengthened my understanding of quality control and regulatory compliance within pharmaceutical settings. Altogether, this diverse journey has equipped me with the scientific and leadership skills I now apply in my role at Croda Pharma, where I lead a team focusing on innovation in excipient development.

Looking at emerging modalities like antibodies and gene therapies, what unique challenges do these new areas pose for excipient development?

Biologics and gene therapies introduce a new level of complexity, which traditional excipients are not always designed to handle. The biggest challenge lies in building meaningful structure property performance relationships, especially when available data is limited. These therapies demand excipients that are tailored for stability, compatibility, and efficacy, yet the underlying mechanisms can be difficult to interpret. At Croda, we are working to bridge these gaps by generating relevant data, applying advanced characterisation tools, and collaborating closely with formulation scientists. This approach allows us to support innovation while ensuring our excipients offer true functional value for these novel treatments.

Oxidative stability is a known issue in formulations with excipients like polysorbates. How do you address this?

Oxidative degradation is a well recognised risk in biologic formulations, especially those using polysorbates. At Croda Pharma, we address this challenge by focusing on excipient purity through our Super Refined technology. This special process dramatically reduces residual peroxides and other impurities that can trigger instability, leading to improved shelf life and formulation reliability. Beyond manufacturing, we support customers by offering guidance on optimal storage, handling, and shipping practices to minimise further oxidative stress. Together, these measures help protect sensitive drug products and ensure consistent performance across the product lifecycle.

Beyond technical hurdles, what are the biggest collaborative challenges in launching new excipient-based solutions?

Developing new excipients is not just a scientific challenge; it is also a collaborative one. Aligning diverse stakeholders, such as suppliers, regulatory experts, and formulation teams, can be complex, especially at early stages. Often, I find myself coordinating efforts across procurement, quality, and analytical teams to ensure everything progresses smoothly. Clear communication is essential, as is establishing shared goals from the outset. At Croda, we emphasise transparency and alignment to maintain momentum. When managed well, these collaborations become a strength, enabling us to move faster and deliver solutions that meet both regulatory and market needs.

How do you stay current with advancements in excipient science and regulatory trends? Any tips for peers?

Staying current requires curiosity and an active approach to learning. I regularly read scientific publications, patents, and regulatory updates, but I also monitor industry trends through marketing material, social media, competitor activities, and even conversations with customers to understand practical challenges and emerging needs. In addition, I explore emerging tools, including AI, which can be surprisingly helpful for generating new perspectives. My advice to fellow scientists is to cast a wide net, remain open minded, and be willing to learn from both traditional and unconventional sources.

When you are not working, what helps you recharge and stay inspired?

Creativity and focus come from balance. Outside of work, I make time for physical activity, good nutrition, and quality time with family. These routines help me stay energised and mentally clear. I also enjoy cooking, listening to music, and tackling creative or technical challenges in my personal time. Interestingly, some of my best ideas have surfaced while I was completely away from the lab. Taking time to disconnect allows the mind to reset and often leads to fresh, more innovative thinking when I return to work.